Two China biotechs drop U.S. IPO plans for $800 million Hong Kong floats: sources

HONG KONG (Reuters) – Two Chinese biotechs have axed plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in on new rules to woo early-stage drug developers, sources said. Fidelity Investments-backed …
( read original story …)


Related Post

A Look At Hong Kong Finance Investment Holding Gro...
views 12
Building up an investment case requires looking at...
From Vancouver to Hong Kong and back again: why so...
views 11
Some British Columbians who moved to Hong Kong for...
Hong Kong Business hails the most exceptional ente...
views 11
HONG KONG, Jan. 18, 2019 /PRNewswire/ -- On its 15...
Hong Kong light show proving a hit with residents ...
views 13
A photogenic light show illuminating the heart of ...
Hong Kong Bourse May Reverse Thursday’s Loss...
views 18
BOC Hong Kong dropped 1.01 percent, Sands China sh...
New transport links boost business and tourism for...
views 22
Hong Kong's new high-speed train station, along wi...
A bunch of stocks in Hong Kong crashed 70% without...
views 20
The stock price of several Hong Kong-listed compan...
Hong Kong’s pro-democracy and pro-Beijing camps jo...
views 24
In a rare show of unity, legislators from across H...
Hong Kong market slips in late trading after clutc...
views 21
It got an early boost from the latest announcement...
Hong Kong consumers ready to embrace Open Banking
views 24
As Hong Kong prepares for a new era of Open bankin...